European Commission grants marketing authorization for NEZGLYAL® (leriglitazone), the first pharmacological treatment approved for cerebral adrenoleukodystrophy (cALD), a rare neurodegenerative disease

By News Medical September 26, 2026 #adrenoleukodystrophy, #Approved, #authorizationfor, #cALD, #Cerebral, #Commission, #disease, #European, #grants, #Health, #leriglitazone, #marketing, #Medical, #medicine, #neurodegenerative, #NEZGLYAL, #Pharmacological, #Rare, #Treatment

Neuraxpharm Group and Minoryx Therapeutics, today announce that the European Commission (EC) has granted marketing authorization under exceptional circumstances for NEZGLYAL® (leriglitazone), an orally bioavailable, brain penetrating, selective PPAR gamma agonist, as a treatment for male cALD patients, aged 2-12 years with Gadolinium (Gd)-negative brain lesions.

European Commission grants marketing authorization for NEZGLYAL® (leriglitazone), the first pharmacological treatment approved for cerebral adrenoleukodystrophy (cALD), a rare neurodegenerative disease

By News Medical

You Missed

European Commission grants marketing authorization for NEZGLYAL® (leriglitazone), the first pharmacological treatment approved for cerebral adrenoleukodystrophy (cALD), a rare neurodegenerative disease

Virtual reality and music may help lower blood pressure during emergencies

Drone-delivered AEDs could reduce defibrillation delays after cardiac arrest

UCLA researchers present new radiation advances at ASTRO 2026

By News Medical

Related Post

You Missed